Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
28 Oct 2021
Historique:
received: 21 09 2021
revised: 14 10 2021
accepted: 25 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 6 1 2022
Statut: epublish

Résumé

Polyphenols from olive oil are endowed with several biological activities. Chemical modifications have been recently applied to these compounds to improve their therapeutic activity in different pathological settings, including cancer. Herein, we describe the in vitro effects on multiple myeloma (MM) cells of oleil hydroxytyrosol (HTOL), a synthetic fatty ester of natural hydroxytyrosol with oleic acid. HTOL reduced the viability of various human MM cell lines (HMCLs), even when co-cultured with bone marrow stromal cells, triggering ER stress, UPR and apoptosis, while it was not cytotoxic against healthy peripheral blood mononuclear cells or B lymphocytes. Whole-transcriptome profiling of HTOL-treated MM cells, coupled with protein expression analyses, indicate that HTOL antagonizes key survival pathways for malignant plasma cells, including the undruggable IRF4-c-MYC oncogenic axis. Accordingly, c-MYC gain- and loss-of-function strategies demonstrate that HTOL anti-tumor activity was, at least in part, due to c-MYC targeting. Taken together, these findings underscore the anti-MM potential of HTOL, providing the molecular framework for further investigation of HTOL-based treatments as novel anti-cancer agents.

Identifiants

pubmed: 34769070
pii: ijms222111639
doi: 10.3390/ijms222111639
pmc: PMC8584245
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
3,4-dihydroxyphenylethanol 10597-60-1
Phenylethyl Alcohol ML9LGA7468

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Association for Cancer Research
ID : IG24449
Organisme : Italian MOH
ID : GR2016-02361523

Références

Cancers (Basel). 2019 Feb 18;11(2):
pubmed: 30781685
Cancers (Basel). 2019 Jul 16;11(7):
pubmed: 31315220
Cancer Res. 2007 Dec 15;67(24):11914-23
pubmed: 18089822
J Exp Clin Cancer Res. 2018 Jul 27;37(1):173
pubmed: 30053872
Sci Rep. 2018 Apr 26;8(1):6557
pubmed: 29700321
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Cancer Cell. 2013 Apr 15;23(4):435-49
pubmed: 23541952
J Transl Med. 2014 Aug 03;12:219
pubmed: 25086598
Leukemia. 2015 Nov;29(11):2173-83
pubmed: 25987254
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Int J Mol Sci. 2019 May 09;20(9):
pubmed: 31075954
Mol Cell Oncol. 2015;2(4):e1006077
pubmed: 26380379
Curr Med Chem. 2013;20(19):2467-75
pubmed: 23521677
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019064
Biomed Res Int. 2016;2016:6504593
pubmed: 26881223
J Biotechnol. 2012 Jan 20;157(2):344-9
pubmed: 22138637
Clin Cancer Res. 2016 Nov 15;22(22):5419-5427
pubmed: 28151709
Cancers (Basel). 2020 Sep 03;12(9):
pubmed: 32899221
Oncotarget. 2016 Jan 19;7(3):2367-78
pubmed: 26496024
Br J Pharmacol. 2020 Mar;177(6):1409-1423
pubmed: 31368509
Nat Prod Rep. 2021 Mar 1;38(3):444-469
pubmed: 33300916
Curr Med Chem. 2020;27(2):187-215
pubmed: 29956610
J Agric Food Chem. 2009 Dec 9;57(23):11161-7
pubmed: 19908866
J Nat Prod. 2011 Nov 28;74(11):2377-81
pubmed: 22014120
Int J Mol Sci. 2014 Oct 14;15(10):18508-24
pubmed: 25318054
Eur J Pharmacol. 2014 Oct 5;740:209-17
pubmed: 25046839
Biochemistry (Mosc). 2015 Aug;80(8):972-89
pubmed: 26547065
Nutr Rev. 2010 Apr;68(4):191-206
pubmed: 20416016
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
Blood. 2018 Sep 6;132(10):1050-1063
pubmed: 29997223
Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):67-79
pubmed: 16569345
Clin Cancer Res. 2009 May 1;15(9):2954-61
pubmed: 19383829
Eur J Pharm Biopharm. 2015 Jan;89:175-81
pubmed: 25497179
Front Pharmacol. 2018 Oct 10;9:1144
pubmed: 30364171
Haematologica. 2018 Aug;103(8):e368-e371
pubmed: 29545338
J Agric Food Chem. 2010 Jul 14;58(13):8021-6
pubmed: 20524658

Auteurs

Katia Todoerti (K)

Department of Oncology and Hemato-Oncology, University of Milano, 20122 Milano, Italy.
Hematology Unit, Fondazione Cà Granda IRCCS, Ospedale Maggiore Policlinico, 20122 Milano, Italy.

Maria Eugenia Gallo Cantafio (ME)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Manuela Oliverio (M)

Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Giada Juli (G)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Carmine Rocca (C)

Laboratory of Cellular and Molecular Cardiovascular Physiology, Department of Biology, Ecology and Earth Sciences (Di.B.E.S.T.), University of Calabria, 87036 Rende, Italy.

Rita Citraro (R)

Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Pierfrancesco Tassone (P)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Antonio Procopio (A)

Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Giovambattista De Sarro (G)

Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Antonino Neri (A)

Department of Oncology and Hemato-Oncology, University of Milano, 20122 Milano, Italy.
Hematology Unit, Fondazione Cà Granda IRCCS, Ospedale Maggiore Policlinico, 20122 Milano, Italy.

Giuseppe Viglietto (G)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Nicola Amodio (N)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH